ACADIA Pharmaceuticals Inc (ACAD)
14.60
-0.02
(-0.14%)
USD |
NASDAQ |
Nov 05, 09:44
ACADIA Pharmaceuticals Net Income (Quarterly): 33.39M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 33.39M |
| March 31, 2024 | 16.56M |
| December 31, 2023 | 45.80M |
| September 30, 2023 | -65.18M |
| June 30, 2023 | 1.114M |
| March 31, 2023 | -43.02M |
| December 31, 2022 | -41.72M |
| September 30, 2022 | -27.18M |
| June 30, 2022 | -34.01M |
| March 31, 2022 | -113.06M |
| December 31, 2021 | -43.09M |
| September 30, 2021 | -14.46M |
| June 30, 2021 | -43.87M |
| March 31, 2021 | -66.45M |
| December 31, 2020 | -66.76M |
| September 30, 2020 | -84.66M |
| June 30, 2020 | -42.14M |
| March 31, 2020 | -88.02M |
| December 31, 2019 | -53.04M |
| September 30, 2019 | -41.98M |
| June 30, 2019 | -54.94M |
| March 31, 2019 | -85.30M |
| December 31, 2018 | -65.49M |
| September 30, 2018 | -62.14M |
| June 30, 2018 | -63.27M |
| Date | Value |
|---|---|
| March 31, 2018 | -54.30M |
| December 31, 2017 | -68.87M |
| September 30, 2017 | -65.25M |
| June 30, 2017 | -67.44M |
| March 31, 2017 | -87.84M |
| December 31, 2016 | -78.70M |
| September 30, 2016 | -71.61M |
| June 30, 2016 | -71.32M |
| March 31, 2016 | -49.76M |
| December 31, 2015 | -45.78M |
| September 30, 2015 | -38.91M |
| June 30, 2015 | -39.38M |
| March 31, 2015 | -40.38M |
| December 31, 2014 | -28.37M |
| September 30, 2014 | -24.79M |
| June 30, 2014 | -21.50M |
| March 31, 2014 | -17.83M |
| December 31, 2013 | -12.05M |
| September 30, 2013 | -10.70M |
| June 30, 2013 | -9.081M |
| March 31, 2013 | -6.123M |
| December 31, 2012 | -6.81M |
| September 30, 2012 | -2.402M |
| June 30, 2012 | -5.419M |
| March 31, 2012 | -6.218M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-113.06M
Minimum
Mar 2022
45.80M
Maximum
Dec 2023
-38.41M
Average
-43.02M
Median
Mar 2023
Net Income (Quarterly) Benchmarks
| Biogen Inc | 388.50M |
| Madrigal Pharmaceuticals Inc | -106.96M |
| Supernus Pharmaceuticals Inc | 19.92M |
| Geovax Labs Inc | -5.064M |
| Myomo Inc | -1.122M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 241.96M |
| Total Expenses (Quarterly) | 211.53M |
| EPS Diluted (Quarterly) | 0.20 |
| Enterprise Value | 1.924B |
| Gross Profit Margin (Quarterly) | 92.47% |
| Profit Margin (Quarterly) | 13.80% |
| Earnings Yield | 1.23% |
| Operating Earnings Yield | 0.94% |
| Normalized Earnings Yield | 1.233 |